Literature DB >> 24647359

H2A-DUBbing the mammalian epigenome: expanding frontiers for histone H2A deubiquitinating enzymes in cell biology and physiology.

Jad I Belle1, Anastasia Nijnik2.   

Abstract

Posttranslational modifications of histone H2A through the attachment of ubiquitin or poly-ubiquitin conjugates are common in mammalian genomes and play an important role in the regulation of chromatin structure, gene expression, and DNA repair. Histone H2A deubiquitinases (H2A-DUBs) are a group of structurally diverse enzymes that catalyze the removal ubiquitin from histone H2A. In this review we provide a concise summary of the mechanisms that mediate histone H2A ubiquitination in mammalian cells, and review our current knowledge of mammalian H2A-DUBs, their biochemical activities, and recent developments in our understanding of their functions in mammalian physiology.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chromatin; DNA repair; Deubiquitinase; Histone H2A; Transcriptional regulation

Mesh:

Substances:

Year:  2014        PMID: 24647359     DOI: 10.1016/j.biocel.2014.03.004

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  16 in total

Review 1.  Decision for cell fate: deubiquitinating enzymes in cell cycle checkpoint.

Authors:  Key-Hwan Lim; Myoung-Hyun Song; Kwang-Hyun Baek
Journal:  Cell Mol Life Sci       Date:  2016-01-13       Impact factor: 9.261

2.  BMI1-RING1B is an autoinhibited RING E3 ubiquitin ligase.

Authors:  Asad M Taherbhoy; Oscar W Huang; Andrea G Cochran
Journal:  Nat Commun       Date:  2015-07-07       Impact factor: 14.919

3.  A role for the histone H2A deubiquitinase MYSM1 in maintenance of CD8+ T cells.

Authors:  Michael Förster; Rupinder K Boora; Jessica C Petrov; Nassima Fodil; Isabella Albanese; Jamie Kim; Philippe Gros; Anastasia Nijnik
Journal:  Immunology       Date:  2017-02-20       Impact factor: 7.397

4.  MYSM1 maintains ribosomal protein gene expression in hematopoietic stem cells to prevent hematopoietic dysfunction.

Authors:  Jad I Belle; HanChen Wang; Amanda Fiore; Jessica C Petrov; Yun Hsiao Lin; Chu-Han Feng; Thi Tuyet Mai Nguyen; Jacky Tung; Philippe M Campeau; Uta Behrends; Theresa Brunet; Gloria Sarah Leszinski; Philippe Gros; David Langlais; Anastasia Nijnik
Journal:  JCI Insight       Date:  2020-07-09

5.  The BAP1/ASXL2 Histone H2A Deubiquitinase Complex Regulates Cell Proliferation and Is Disrupted in Cancer.

Authors:  Salima Daou; Ian Hammond-Martel; Nazar Mashtalir; Haithem Barbour; Jessica Gagnon; Nicholas V G Iannantuono; Nadine Sen Nkwe; Alena Motorina; Helen Pak; Helen Yu; Hugo Wurtele; Eric Milot; Frédérick A Mallette; Michele Carbone; El Bachir Affar
Journal:  J Biol Chem       Date:  2015-09-28       Impact factor: 5.157

Review 6.  Ubiquitin ligases in oncogenic transformation and cancer therapy.

Authors:  Daniela Senft; Jianfei Qi; Ze'ev A Ronai
Journal:  Nat Rev Cancer       Date:  2017-12-15       Impact factor: 60.716

Review 7.  Ubiquitin-dependent regulation of transcription in development and disease.

Authors:  Kevin G Mark; Michael Rape
Journal:  EMBO Rep       Date:  2021-03-28       Impact factor: 8.807

Review 8.  Fine-tuning the ubiquitin code at DNA double-strand breaks: deubiquitinating enzymes at work.

Authors:  Elisabetta Citterio
Journal:  Front Genet       Date:  2015-09-08       Impact factor: 4.599

9.  Repression of p53-target gene Bbc3/PUMA by MYSM1 is essential for the survival of hematopoietic multipotent progenitors and contributes to stem cell maintenance.

Authors:  J I Belle; J C Petrov; D Langlais; F Robert; R Cencic; S Shen; J Pelletier; P Gros; A Nijnik
Journal:  Cell Death Differ       Date:  2016-01-15       Impact factor: 15.828

Review 10.  DUBbing Cancer: Deubiquitylating Enzymes Involved in Epigenetics, DNA Damage and the Cell Cycle As Therapeutic Targets.

Authors:  Adan Pinto-Fernandez; Benedikt M Kessler
Journal:  Front Genet       Date:  2016-07-28       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.